# Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

> **NCT07220460** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 200 (estimated)

## Conditions studied

- Bipolar I or II Disorder

## Interventions

- **DRUG:** ABBV-932

## Key facts

- **NCT ID:** NCT07220460
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07220460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07220460, "Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07220460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*